지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 424 - 435 (12page)
이용수
초록· 키워드
오류제보하기
Purpose A recent phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy is a new treatment paradigm for advanced nonsquamous non-small cell lung cancer (NSCLC). The majority of patients enrolled in PARAMOUNT were Caucasian (94%). We reviewed efficacy and safety data from two clinical trials, which enrolled East Asian (EA) patients, to supplement data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC.
Materials and Methods Study S110 was a phase II, multicenter, randomized, controlled, open-label trial in never-smoker, chemonaïve, EA patients (n=31) with locally advanced or metastatic nonsquamous NSCLC (n=27). Study JMII was a multicenter, open-label, single-arm, postmarketing, clinical trial in Japanese patients (n=109) with advanced nonsquamous NSCLC.
PARAMOUNT was a multicenter, randomized, double-blind, placebo-controlled trial in patients with advanced nonsquamous NSCLC.
Results In EA patients with nonsquamous NSCLC, the median progression-free survival (PFS) for pemetrexed continuation maintenance therapy was 4.04 months (95% confidence interval [CI], 3.22 to 5.29 months) in study S110 and 3.9 months (95% CI, 3.2 to 5.2 months) in study JMII. The median PFS for pemetrexed continuation maintenance therapy in PARAMOUNT was 4.1 months (95% CI, 3.2 to 4.6 months). Pemetrexed continuation maintenance therapy in EA patients in studies S110 and JMII did not lead to any unexpected safety events, and was consistent with PARAMOUNT’s safety profile.
Conclusion The efficacy and safety data in the EA trials were similar to those in PARAMOUNT despite differences in patient populations and study designs. These data represent consistent evidence for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Ahn MJ / 2012 / Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker pa
Azzoli CG / 2012 / 2011 Focused update of 2009American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
Belani CP / 2012 / Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung
Ciuleanu T / 2009 / Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer : a randomised, double-blind, phas
Gridelli C / 2012 / Safety, resource use, and quality of life in paramount : a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cispl
Azzoli CG / 2012 / 2011 Focused update of 2009American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
Belani CP / 2012 / Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung
Ciuleanu T / 2009 / Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer : a randomised, double-blind, phas
Gridelli C / 2012 / Safety, resource use, and quality of life in paramount : a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cispl
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Tuberculosis and Respiratory Diseases
2018 .01
-
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Cancer Research and Treatment
2015 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Cancer Research and Treatment
2019 .01
-
Pemetrexed in Treating Patients with Metastatic Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer
Cancer Research and Treatment
2021 .01
-
Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Yonsei Medical Journal
2018 .01
-
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Cancer Research and Treatment
2015 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Cancer Research and Treatment
2016 .01
-
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Cancer Research and Treatment
2017 .01
-
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort Study
Cancer Research and Treatment
2022 .10
-
Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?
예방의학회지
2019 .01
-
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
Cancer Research and Treatment
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0